German Centre for Infection Research HIV Translational Platform
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02149004 |
|
Recruitment Status :
Recruiting
First Posted : May 29, 2014
Last Update Posted : October 27, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Despite major advances in therapy and management, HIV/AIDS continues to be a major cause of infectious disease morbidity and mortality on a global scale. The discovery of effective antiretroviral treatment has turned HIV infection into a manageable chronic disease in most patients with access to care. However, the different economic and epidemiologic situation in developing and developed countries requires different research priorities, so that three main challanges are universal and in focus of research of the DZIF HIV Translational Platform:
- Prevention of HIV infection
- Long-term life with HIV
- HIV cure
The "Translation Reserach HIV" will bring together clinical researchers in HIV infection in order to develop new treatment options to the above mentioned main challanges. It will take advantage of existing expertise (e.g. basic science, novel targets for treatment and HIV eradiation) of the partner sites. This platform is necessary because Germany's HIV research has suffered in the past from a lack of integration between its excellent basic science and clinical research. In addition, there was too little integration into networks that address the main international challenges. There is an urgent need to link these research strands through dedicated structures emphasising the translation of preclinical results into new therapies.
| Condition or disease |
|---|
| HIV |
Structure
The DZIF HIV Translational Platform belongs to the HIV the Thematic Translational Units (TTUs) of the German Centre for Infection Research (DZIF), which is founded by the Federal Ministry of Education and Research (BMBF). The national, multi-centre structure of the DZIF bringing together selceted universities, university hospitals, and non-university research institutes and translational efforts focussing on distinct infectious diesease-related health problems are co-ordinated by the TTUs. The TTU HIV is located in six DZIF partner sites in Germany: Bonn-Cologne, Brunswick-Hannover, Gießen-Marburg-Langen, Hamburg, Heidelberg, Munich.
Mission and Objectives
Prevention of HIV:
The main tools for effective prevention include vaccines, microbicides, preventive therapy and induction of behavioral change. Currently, few groups in Germany have specific preclinical expertise in this area. This expertise needs to be further developed and integrated in the DZIF to be able to implement internationally competitive HIV vaccine and microbicide programmes.
Long-term life with HIV:
This challenge is equally relevant for the developing and developed world. DZIF researchers have made many internationally visible contributions to management of HIV infection in the past. They have extensive experience in clinical studies in the HIV field and have played a major role in the clinical development of new drugs for HIV therapy (e.g. maraviroc, raltegravir). They are also intensively involved in the establishment of clinical guidelines for management of HIV infection.
HIV cure:
Antiretroviral therapy can completely suppress HIV replication below the limit of detection for sustained periods of time, but cannot eradicate the virus from silent reservoirs. Accordingly, life-long therapy is needed and interruption of therapy always leads to resurgence of viral spread and disease. Several approaches have been suggested to eliminate silently infected cells or the HIV genomes integrated in these cells. These approaches are currently mostly at the stage of basic research or early preclinical development and need to be developed in the translational chain. While significant knowledge exists about the nature of silent reservoirs, the number and clonality of viral integration sites is currently largely unknown and needs to be further investigated to develop virus eradication strategies and therapies.
The aim of the DZIF HIV Translational Platform is to comprehensively and collaboratively analyze the above mentioned aspects by using cohorts of HIV infected patients in different stages and with different courses of disease. These cohorts have been established by the participating partner sites, which will be coordinated and extended by the focus site in Bonn-Cologne.
This study protocol is the framework and platform for future substudies.
| Study Type : | Observational |
| Estimated Enrollment : | 10000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Translational Research Platform of the TTU HIV of the German Center for Infection Research (DZIF) |
| Study Start Date : | April 2015 |
| Estimated Primary Completion Date : | January 2035 |
| Estimated Study Completion Date : | January 2035 |
| Group/Cohort |
|---|
| Site Bonn |
| Site Heidelberg |
| Site Munich |
| Site Hamburg |
| Site Hannover |
| Site Cologne |
| Site Freiburg |
| Site Frankfurt |
| Site Essen |
- Incidence of new HIV infections in Germany [ Time Frame: Up to 20 years ]Overall long-term goal of the platform is to develop a translation strategy for the preclinical results concerning HIV prevention from all German research groups with outstanding expertise. Specific outcome measures will be detailed in future subprojects.
- Incidence of chronic organ failure and malignant diseases in HIV infected patients [ Time Frame: Up to 20 years ]Overall long-term goal of this platform is to focus on co-infections, organ damage and malignant diseases. Research on identifying new correlates of protection and long term viral control will contribute to improved management of HIV infection. Specific outcome measures will be detailed in future subprojects.
- Sustained viral response rate 12 months after discontinuation of ART [ Time Frame: Up to 20 years ]Overall long-term goal of this platform is to eliminate silently infected cells or the HIV genomes integrated in these cells. These approaches are currently mostly at the stage of basic research or early preclinical development and need to be developed in the translational chain. Specific outcome measures will be detailed in future subprojects.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- HIV positive
Exclusion Criteria:
- None
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02149004
| Contact: Jörg Janne Vehreschild, MD | +49 221 478 86973 | janne.vehreschild@ctuc.de | |
| Contact: Gerd Fätkenheuer, MD | +49 221 478 3324 | g.faetkenheuer@uni-koeln.de |
| Germany | |
| University Hospital of Cologne | Recruiting |
| Cologne, North Rhine-Westphalia, Germany, 50931 | |
| Contact: Jörg Janne Vehreschild, MD +49 221 478 86973 janne.vehreschild@ctuc.de | |
| Principal Investigator: Jörg Janne Vehreschild, MD | |
| Principal Investigator: | Jörg Janne Vehreschild, MD | University Hospital of Cologne |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. med. Jörg Janne Vehreschild, Coordinating Investigator, University Hospital of Cologne |
| ClinicalTrials.gov Identifier: | NCT02149004 |
| Other Study ID Numbers: |
DZIF_HIV |
| First Posted: | May 29, 2014 Key Record Dates |
| Last Update Posted: | October 27, 2017 |
| Last Verified: | October 2017 |
|
Human immunodeficiency virus (HIV) Prevention Long-term life Cure Cohort |
|
Infections |